论文部分内容阅读
化疗对非小细胞肺癌的疗效已到达平台期,研发更为有效、易耐受的治疗策略势在必行。肿瘤生物学分子机制研究孕育了分子靶向治疗。VEGF、EGFR相关信号通路在肿瘤发生、发展中发挥重要作用,是抗肿瘤药物的重要分子靶点。贝伐单抗联合化疗和小分子酪氨酸激酶抑制剂(埃罗替尼和吉非替尼)分别成为非小细胞肺癌的一、二线治疗方案。本文将综述多种抗-VEGF和抗-EGFR新药在进展期非小细胞肺癌治疗中的临床应用。
The efficacy of chemotherapy for non-small cell lung cancer has reached a plateau, the development of more effective and easy to tolerate treatment strategy is imperative. Molecular biology of tumor biology gave birth to molecular targeted therapy. VEGF, EGFR-related signaling pathways play an important role in tumorigenesis and development and are important molecular targets of antitumor drugs. Bevacizumab combined with chemotherapy and small molecule tyrosine kinase inhibitors (erlotinib and gefitinib), respectively, as a second-line treatment of non-small cell lung cancer. This article reviews the clinical application of various anti-VEGF and anti-EGFR agents in the treatment of advanced non-small cell lung cancer.